Search

Your search keyword '"Miyakita, Yasuji"' showing total 396 results

Search Constraints

Start Over You searched for: Author "Miyakita, Yasuji" Remove constraint Author: "Miyakita, Yasuji"
396 results on '"Miyakita, Yasuji"'

Search Results

101. First case of human neurocoenurosis caused by Taenia serialis: A case report

106. Assessment of the Diagnostic Utility of Serum MicroRNA Classification in Patients With Diffuse Glioma

107. NQPC-10 END-OF-LIFE PHASE OF GLIOBLASTOMA

114. ACT-14 A FIRST-IN-HUMAN STUDY OF MUTANT IDH1 INHIBITOR DS-1001B IN PATIENTS WITH RECURRENT GLIOMAS

115. ACTR-17. DIAGNOSTIC UTILITY OF SERUM microRNA CLASSIFICATION IN DIFFUSE GLIOMA

117. Phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001b in patients with recurrent or progressive IDH1 mutant gliomas.

119. Diagnostic Ability of Serum microRNA Classification in Diffuse Glioma: A Retrospective Comprehensive Analysis with Case-Control Study

122. NCMP-09. ISOCITRATE DEHYDROGENASE MUTATIONS AND INCREASED TISSUE 2-HYDROXYGLUTARATE CONCENTRATION MIGHT BE RELATED WITH SEIZURE ONSET IN PATIENTS WITH GLIOMAS

123. INTRAVASCULAR LYMPHOMA OF THE CENTRAL NERVOUS SYSTEM PRESENTING AS MULTIPLE CEREBRAL INFARCTIONS

124. Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2Ahomozygous deletion in the assessment of adult-type infiltrating astrocytoma

125. Impact of Surgical Margin in Skull Base Surgery for Head and Neck Sarcomas

126. Additional file 3: Figure S1. of A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas

128. Outcomes of Surgery followed by Local Brain Radiotherapy Compared with Surgery followed by Whole Brain Radiotherapy for Single Brain Metastasis

129. MPTH-22. SERUM 2-HYDROXYGLUTARATE (2HG) LEVELS ARE CORRELATED WITH TISSUE 2HG LEVELS IN ISOCITRATE DEHYDROGENASE 1 AND 2 GENES (IDH1/2)-MUTATED GLIOMAS BUT NOT IN IDH1/2-WILDTYPE GLIOMAS

130. A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas

131. Health-related quality of life in outpatients with primary central nervous system lymphoma after radiotherapy and high-dose methotrexate chemotherapy

132. Frequent false‐negative immunohistochemical staining with IDH1 (R132H)‐specific H09 antibody on frozen section control slides: a potential pitfall in glioma diagnosis.

133. Effects of Surgery With Salvage Stereotactic Radiosurgery Versus Surgery With Whole-Brain Radiation Therapy in Patients With One to Four Brain Metastases (JCOG0504): A Phase III, Noninferiority, Randomized Controlled Trial.

135. EPIG-18PYROSEQUENCING ANALYSIS OF THE MGMT PROMOTER METHYLATION STATUS IN NEWLY DIAGNOSED GLIOBLASTOMA CORRELATES WITH VOLUMETRIC CHANGES OF UNRESECTED ENHANCED LESIONS IN MRI AFTER STANDARD RADIATION AND TEMOZOLOMIDE THERAPY

138. Molecular imaging using PET for breast cancer

140. Olfactory Preservation in Craniofacial Resection of Tumor Invading Hemianterior Skull Base: Operative Video.

147. The necessity of long-term follow-up including spinal examination after successful initial treatment of intracranial germinoma: case reports.

148. Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305)

150. IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy

Catalog

Books, media, physical & digital resources